Journal
NATURE AND SCIENCE OF SLEEP
Volume 12, Issue -, Pages 709-719Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/NSS.S264140
Keywords
narcolepsy; pitolisant; histamine 3 receptor; excessive daytime sleepiness; cataplexy
Categories
Funding
- NIA NIH HHS [R01 AG066870, R21 AG059179, R01 AG056682] Funding Source: Medline
Ask authors/readers for more resources
Narcolepsy is a sleep disorder marked by chronic, debilitating excessive daytime sleepiness and can be associated with cataplexy, sleep paralysis and sleep-related hallucinations. Pharmacological therapy for narcolepsy primarily aims to increase wakefulness and reduce cataplexy attacks. Pitolisant is a first-in-class agent utilizing histamine to improve wakefulness by acting as an antagonist/inverse agonist of the presynaptic histamine 3 receptor. This review summarizes the clinical efficacy, safety and tolerability of pitolisant in treating the symptoms of narcolepsy. Randomized and observational studies demonstrate pitolisant to be effective in treating both hypersomnolence and cataplexy while generally being well tolerated at prescribed doses. The most common adverse reactions include headache, insomnia and nausea.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available